Analyst Says Gene Therapy Data Update Offers Insights into Potential Pivotal Endpoints
Portfolio Pulse from Vandana Singh
Avrobio Inc's shares are trading higher after announcing follow-up data from a Phase 1/2 trial of gene therapy AVR-RD-04 for cystinosis, showing a durable treatment effect across key measures up to 36 months. The data suggests potential registrational strategies using an accelerated approval pathway.
May 18, 2023 | 6:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avrobio's stock price is up after positive Phase 1/2 trial data for gene therapy AVR-RD-04, which could lead to an accelerated approval pathway.
The positive trial data for Avrobio's gene therapy demonstrates a durable treatment effect, which could lead to an accelerated approval pathway. This news directly impacts the company's stock price, as it shows progress in their product development and potential for future growth. The stock price has already risen by 33.1%, indicating a positive short-term impact.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100